搜索结果101-110 的 6989 / 안암동오피◐존재하는◑▶ yeotop1.com ◀ 안암동OP☽안암동오피ほ안암동키스방♒안암동스파ⅶ안암동건마ⅳ안암동출장

  1. 神经科- 临床试验- 妙佑医疗国际

    Aims, purpose, or objectives: To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the ...

  2. 神经科- 临床试验- 妙佑医疗国际

    This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may ...

  3. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  4. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  5. 神经科- 临床试验- 妙佑医疗国际

    This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may ...

  6. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  7. 神经科- 临床试验- 妙佑医疗国际

    To establish a repository of DNA samples collected prospectively from patients with inherited myopathies of unknown molecular and/or biochemical defect.

  8. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  9. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  10. 神经科- 临床试验- 妙佑医疗国际

    Aims, purpose, or objectives: To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the ...